EQT

EQT is a private equity firm headquartered in Stockholm, Sweden, with additional offices across Europe, North America, and the Asia Pacific region. Established in 1994, the firm specializes in buyouts, expansion capital, and infrastructure investments, focusing on mid-market companies in sectors such as healthcare, technology, industrials, and services. EQT employs a responsible ownership approach and an industrial growth strategy, seeking opportunities in regions with significant growth potential, including Northern and Eastern Europe, Asia, and the United States. The firm invests through various strategies, including private capital, real assets, credit, and public value, and aims to acquire controlling or co-controlling stakes in its portfolio companies, often holding investments for four to eight years. EQT Life Sciences, a notable segment of the firm, targets innovative healthcare and life sciences companies.

Harsh Agarwal

Director

Päivi Arminen

MD

Andreas Aschenbrenner

Partner

Michael Bauer

Partner, Head of Switzerland and Co-Head of EQT's Global Healthcare Sector Team

Daniela Begolo

Managing Director

Ralph Betz

Director of Credit Team

Lennart Blecher

Deputy Managing Partner

Per Georg Braathen

Industrial Advisor

Shannee Braun

Vice President

Marcus Brennecke

PARTNER and CO-HEAD OF EQT PRIVATE EQUITY ADVISORY TEAM

Carolina Brochado

Deputy Head, Advisory Team

Nicolas Brugère

Partner and Head of France

Drew Burdon

Partner

Benjamin Bygott-Webb

Managing Director

Sarah Carr

Investor Relations Manager

Jay Chae

Director, Client Relations and Capital Raising (APAC)

Brian Chang

Partner

Hans Clevers

Venture Partner

Crosby Cook

Partner

Alex Darden

Partner, President and Head of EQT Infrastructure Advisory Team Americas

Mads M. Ditlevsen

Partner & Head of EQT Partners Denmark

Tracy Duong

VP

Asís Echániz

Partner & Head of Spain

Victor Englesson

Partner

Stephen Escudier

Partner

Matthias Fackler

PARTNER and HEAD OF EQT INFRASTRUCTURE ADVISORY TEAM EUROPE

David Forde

Partner

Per Franzén

Head of Private Capital and Deputy Managing Partner

Florian Funk

PARTNER

Anders Gaarud

Public Value Partner

Wolfgang Gorny

Partner, Private Equity

Simon Griffiths

PARTNER and HEAD OF PRIVATE EQUITY ASIA PACIFIC

Fabian Gröne

Partner, Head of Asia

Albert Gustafsson

PARTNER

Sean Ham

Managing Director, Client Relations and Capital Raising (APAC)

Adil Haque

Partner, Client Relations and Capital Raising (Americas)

Jerry He

PARTNER and HEAD OF CHINA, MID MARKET ASIA ADVISORY TEAM

Frank Heckes

PARTNER

Erika Henriksson

PARTNER

Bruno Holthof

Partner

Masoud Homayoun

PARTNER

Andreas Huber

Partner, Vice Chairperson Asia

Morten Hummelmose

HEAD OF CLIENT RELATIONS and CAPITAL RAISING ADVISORY TEAM, PARTNER

Neha Jatar

Managing Director

Conni Jonsson

Co-Founder, Investment Advisory Professional, Chairman, Member of Nomination Committee, Member of Audit Committee & Member of Remuneration Committee

Matthew Kestenbaum

Managing Director

Paul Kim

Managing Director

Jörg Kinberger

PARTNER

Harry Klagsbrun

PARTNER

Martijn Kleijwegt

Managing Partner and Founder

Karin Kleinhans

Investment Associate

Thomas von Koch

Managing Partner and Chief Executive Officer

Nicolas Kollmann

Associate

Andrew Konopelski

Partner and Head of EQT Credit

Vesa Koskinen

PARTNER

Arvindh Kumar

Partner and Co-Head of Technology Sector Team

Eugene Lee

DIRECTOR

Kirk Lepke

Partner

Matthew S. Levine

Partner and Head of Mid Market US

Mikael Lilius

Industrial Advisor

Benjamin Lim

VP

Eric Liu

PARTNER and CO-HEAD OF GLOBAL HEALTHCARE SECTOR TEAM

Robert Maclean

Partner, Private Equity

Paola Maleh

Partner & Head of EMEA

Carlota Sanchez Marco

Investor Relations MD

Anders Misund

Partner and Head of EQT Future Advisory Team.

Arnav Mitra

Director

Martin Mok

Partner and Head of Mid Market Asia

Joep Muijrers

Partner

Rikke Nielsen

PARTNER

Kristiaan Nieuwenburg

Partner and Head of Performance for Private Capital

Daniel Perez

PARTNER

Jannik Kruse Petersen

Partner and Head of Mid Market Europe

Anne Portwich Ph.D

Partner

Arno Poschik

Director

Robert Rackind

PARTNER

Paul de Rome

Partner and Head of Credit Team

Joachim Rothe Ph.D

Managing Partner

Jussi Saarinen

Partner and Head of Client Relations and Capital Raising

Rosa Sammon, Darlene De La

Managing Director, Client Relations and Capital Raising (Americas)

Carlota Sanchez-Marco

Managing Director, Investor Relations

Carlos Santana

Partner

Anthony Santospirito

Partner

Mika Saukkonen

MD

Gordon Shaw

Partner

Christian Sinding

CEO and Managing Partner

Piyush Singhvi

MD

Georg Stadler

PARTNER

Dominik Stein

PARTNER

Anna Sundell

Partner

Angelo Syailendra

DIRECTOR

Tian Tan

VP

Erwin A. Thompson

PARTNER

Matteo Thun

MD

Peter Veldman

Advisor and EFMS Board Member

Felice Verduyn

Partner

Jan Vesely

Partner

Marcus Wallinder

Partner & Deputy Head of Client Relations and Capital Raising

Forrest Wang

MD

Ethan Waxman

Partner

Felice Verduyn-Van Weegen

Investment Associate

Frans Winarto

VP

Hjalmar Winbladh

Partner and Head of Ventures

Matthias Wittkowski

Partner

Ken Wong

PARTNER

James Yu

PARTNER

Julia Zhu

Managing Director

Fredrik Åtting

Partner

John Österlund

MD

426 past transactions

eTheRNA immunotherapies

Series B in 2022
eTheRNA immunotherapies' mission is to help patients to overcome certain cancers and infectious diseases by developing novel immunotherapies that target the fundamental role of dendritic cells in the human immune system. eTheRNA’s proprietary mRNA-based TriMix technology boosts dendritic cells leading to a more comprehensive, sustainable and safer enhancement of the patient’s immune system than any other similar approach investigated until now.

United Talent Agency

Secondary Market in 2022
United Talent Agency (UTA) where they represent actors, writers, directors, recording artists, emerging technology companies, and corporate brands in a variety of industries, including film, television, music, digital media, intellectual property, computer and video games, commercials, voiceovers, endorsements, and entertainment marketing. Some of their clients are Johnny Depp, Harrison Ford, Owen Wilson, Gwyneth Paltrow, Jennifer Lopez, Paul Giamatti, Anthony Hopkins, Tim Robbins, Seth Rogen, James McAvoy, Ewan McGregor, Rachel McAdams, Paul Rudd, Don Cheadle, and Elizabeth Banks.

ImCheck Therapeutics

Series C in 2022
ImCheck Therapeutics SAS is a biotechnology company incorporated in 2015 and based in Marseille, France. The company specializes in designing and developing immunotherapeutics that target the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. With a primary focus on immuno-oncology, ImCheck Therapeutics develops immunomodulatory antibodies aimed at treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company is dedicated to addressing severe unmet medical needs through its innovative approach to cancer treatment and the development of next-generation immunotherapeutics.

Ariceum Therapeutics

Series A in 2022
Ariceum Therapeutics is a privately held radiopharmaceutical firm in the clinical stage that specializes in the detection and targeted treatment of aggressive malignancies, such as neuroendocrine and other hard-to-treat cancers. 177Lu-satoreotide tetraxetan (Satoreotide), the company's primary targeted systemic radiopharmaceutical therapy, is an antagonist of the somatostatin type 2 receptor (SSTR2), which is overexpressed in many neuroendocrine tumors. For the simultaneous diagnosis and targeted radionuclide treatment of neuroendocrine malignancies, some aggressive tumors, and childhood cancer, which currently offers few treatment choices and a poor prognosis, we are developing satoreotide as a "theranostic" pair.

Ardoq

Series D in 2022
Ardoq AS is a company that specializes in developing solutions for documenting complex computer systems. Based in Oslo, Norway, with additional offices in New York, London, and Copenhagen, Ardoq offers a data-driven tool designed for Enterprise Architecture that facilitates digital transformation for organizations. Its software enables users to combine textual documentation with interactive visualizations, allowing for real-time collaboration and the generation of diagrams on the fly. Key features include automatically generated visualizations and model-based documentation, which help users understand the interdependencies between technology and people. Ardoq serves a diverse range of clients, including businesses, developers, project managers, architects, and stakeholders, focusing on helping them plan, execute, and predict the impact of changes across various aspects of their operations. Since its incorporation in 2013, Ardoq has aimed to empower organizations to drive value through successful change.

Perfuze

Series A in 2022
Perfuze develops technology to treat acute ischemic stroke. The company was founded in 2018 and is based in Galway, Ireland.

ViCentra

Series C in 2021
ViCentra B.V., based in Utrecht, the Netherlands, specializes in the development of medical devices, particularly for diabetes management. The company focuses on creating user-friendly and aesthetically pleasing products that aim to enhance the overall experience for individuals managing their health. ViCentra emphasizes the importance of excellent customer experiences and approaches product design with the belief that simplicity and effectiveness lead to better health outcomes. In addition to its operations in the Netherlands, ViCentra also has a presence in the UK, where it continues to innovate in the field of medical devices through dedicated research and development efforts.

Mambu

Series E in 2021
Mambu GmbH is a Berlin-based software-as-a-service provider that specializes in banking solutions for managing credit and deposit products. Established in 2011, the company offers a comprehensive platform that enables financial institutions of all sizes, including fintech startups and traditional banks, to design, launch, and scale their banking portfolios. Mambu's services include loan product development, credit risk assessment, and document management, which enhance operational efficiency and data quality. Its platform supports over 7,000 products and serves more than eight million end customers across 46 countries. Additionally, Mambu facilitates features such as account opening, portfolio management, and task automation, thereby streamlining workflows for its clients. With offices in key global locations, Mambu is positioned to support a diverse range of financial institutions, from retail banks to microfinance organizations.

3Shape

Private Equity Round in 2021
3Shape creates 3D scanners and CAD/CAM software solutions to improve patient care for dental and audiology professionals around the world.

AviadoBio

Series A in 2021
AviadoBio mission is to transform the lives of people living with neurodegenerative disorders by developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The Company’s technology is based on pioneering research from King’s College London and the UK Dementia Research Institute.

HotSpot Therapeutics

Series C in 2021
HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment. The company's platform helps to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspot structures, harnessing the power of data science in its multidisciplinary approach to drug discovery enabling patients to get treatment against several diseases.

DNA Script

Series C in 2021
DNA Script SAS, founded in 2014 and based in Paris, France, specializes in synthetic biology tools. The company focuses on developing innovative DNA synthesis solutions, including oligonucleotides, genes, pathways, and genomes. Its flagship product, the SYNTAX benchtop DNA printer, utilizes groundbreaking enzymatic technology, allowing laboratories to produce their own synthetic oligonucleotides. This capability enhances workflow control and accelerates access to results, thereby facilitating advancements in life sciences and human health.

Egle Therapeutics

Series A in 2021
Egle Therapeutics SAS, a biotechnology company, develops immunotherapies targeting immune suppressor regulatory T-cells for oncology and autoimmune diseases. It develops Treg modulating drug pipeline, which includes computationally designed resurfaced IL-2 proprietary variants to engage or dis-engage Tregs. The company was founded in 2020 and is based in Paris, France.

CFC Underwriting

Private Equity Round in 2021
They are the largest independent MGA in the UK. They provide their insurance products exclusively through authorised insurance brokers in over 60 countries around the world. Wholesale or retail, big or small, generalist or specialist, all of their brokers have access to underwriters who can make fast decisions and provide flexible solutions. By providing market-leading products, great service and configurable online systems, they help their brokers carry out business more easily, efficiently and profitably. That’s probably why they’ve won eight major industry awards in the last year and over 1,500 businesses move their insurance to CFC every month.

LUMA Vision

Series A in 2021
OneProjects Design and Innovation Ltd. develops healthcare technologies for the treatment of cardiac arrhythmias. It offers VERAFEYE, a connected platform technology to revolutionize the treatment of AFib and cardiac arrhythmias. The company was incorporated in 2017 and is based in Dublin, Ireland.

Supplant

Series A in 2021
Cambridge Glycoscience is a biotechnology company based in London, United Kingdom, founded in 2017. The company specializes in developing sugar-free ingredients for the food industry, focusing on creating natural food components derived from agricultural resources. Their innovative products enable food manufacturers to reduce sugar content, enhance fiber levels, and improve gut health-promoting qualities in food items. By leveraging biotechnology, Cambridge Glycoscience aims to support healthier eating options and contribute to the evolving landscape of food production.

made of air

Seed Round in 2021
Made of Air is a radical new biochar-based material designed to combat climate change. Made of 90% atmospheric carbon, our material is a sustainable alternative for use in construction, interiors, furniture and more.

EC - Council

Private Equity Round in 2021
EC-Council Offers IT and e-Business certifications in CEH, CHFI, ECSP, ECIH, ECSA and LPT Programs EC-Council is the leading IT and e-Business certification awarding body and the creator of the world famous Certified Ethical Hacker (CEH), Computer Hacking Forensics Investigator (CHFI), EC-Council Certified Secure Programmer (ECSP), EC-Council Certified Incident Handler (ECIH) and EC-Council Certified Security Analyst (ECSA)/License Penetration Tester (LPT) programs. For a complete list of certifications, please visit http://cert.eccouncil.org. EC-Council has trained over 80,000 individuals and certified more than 30,000 security professionals from such fine organizations as the US Army, the FBI, Microsoft, IBM and the United Nations. EC-Council's certifications are recognized worldwide and have received endorsements from various government agencies including: - The US Federal Government via the Montgomery GI Bill, - National Security Agency (NSA) and the Committee on National Security Systems (CNSS). To learn more about EC-Council, please visit: www.eccouncil.org. Share Us At: Facebook: http://www.facebook.com/ECCouncil LinkedIn: http://www.linkedin.com/organization/ec-council

Amolyt Pharma

Series B in 2021
Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company's leading programs include AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining sustained calcium levels in the blood, and AZP-3404, which features a novel mechanism of action that may help restore fat and glucose metabolism. Through its innovative approach, Amolyt Pharma seeks to provide effective treatments for patients suffering from critical and rare metabolic conditions.

Blume Global

Private Equity Round in 2021
Blume Global Inc. develops a cloud-based digital platform that connects global supply chains into one ecosystem. Its digital platform enables supply chain pioneers and visionaries to manage their trading partnerships and get real-time visibility to drive efficiency, customer satisfaction, and growth. The company offers its solutions in the areas of assets, logistics, visibility, optimization, and finance. It serves ocean carriers, logistics service providers, and asset owners in retail, consumer packaged goods, hi-tech, healthcare and life science, and automotive industries. Blume Global Inc. was formerly known as REZ-1, Inc. and changed its name to Blume Global Inc. in September 2018. The company was founded in 1993 and is based in Pleasanton, California with a regional office in Hong Kong.

Formo

Series A in 2021
Formo, formerly known as LegenDairy Foods GmbH, is a Berlin-based company that pioneers the production of dairy products through biotechnology. As Europe's first cell-ag company, Formo specializes in creating real dairy products without the use of cows, employing innovative fermentation and bioprocess engineering techniques. The team consists of food scientists and engineers dedicated to advancing sustainable alternatives in the dairy industry. By leveraging biotechnology, Formo aims to provide consumers with high-quality dairy options while addressing environmental concerns associated with traditional dairy farming.

Formo

Series A in 2021
Formo, formerly known as LegenDairy Foods GmbH, is a Berlin-based company that pioneers the production of dairy products through biotechnology. As Europe's first cell-ag company, Formo specializes in creating real dairy products without the use of cows, employing innovative fermentation and bioprocess engineering techniques. The team consists of food scientists and engineers dedicated to advancing sustainable alternatives in the dairy industry. By leveraging biotechnology, Formo aims to provide consumers with high-quality dairy options while addressing environmental concerns associated with traditional dairy farming.

Storytel

Post in 2021
Storytel AB provides streaming services for audiobooks and e-books through subscription models, operating under the Storytel and Mofibo brands. Founded in 2005, the company has established itself as a leader in this sector across various countries, including Sweden, Norway, Denmark, Finland, the Netherlands, Poland, Germany, Spain, and India, among others. In addition to its streaming services, Storytel publishes audiobooks primarily through its own publisher, Storyside, and has expanded its reach in the publishing industry by acquiring several publishing houses such as Massolit and B. Wahlström. The company also offers digital subscriptions for newspapers and magazines and publishes physical books through notable imprints like Norstedts and Rabén & Sjögren. Headquartered in Stockholm, Sweden, Storytel continues to enhance its offerings in the growing digital reading and listening market.

Cardior Pharmaceuticals

Series B in 2021
Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, established in 2016. The company specializes in the development of non-coding RNA-based therapeutics aimed at treating and preventing heart disease, which is the leading cause of death in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor designed to target a critical microRNA that regulates harmful changes in the heart resulting from stress or injury. Cardior Pharmaceuticals is positioned as a planned academic spin-off, emphasizing innovative approaches to address significant cardiovascular health challenges.

Visus Therapeutics

Debt Financing in 2021
Visus Therapeutics is a clinical-stage company developing innovative medicines to improve the vision for people around the world.

T-knife

Series B in 2021
T-knife is a developer of T cell receptors intended for T cell therapy of cancer.The company uses a humanized TCR mice platform to carry human TCRαβ gene loci and recombine a broad repertoire of human TCRs, enabling the efficient generation and virtual selection of cell receptors for any human tumor antigen.

Covanta

Acquisition in 2021
Covanta Holding Corporation (Covanta) is a holding company. The Company is a owner and operator of infrastructure for the conversion of waste to energy ( energy-from-waste or EfW), as well as other waste disposal and renewable energy production businesses. Covanta conduct all of its operations through subsidiaries which are engaged predominantly in the businesses of waste and energy services. The Company has one segment which is Americas and consists of waste and energy services operations primarily in the United States and Canada. The Company owns and holds interests in energy-from-waste facilities in China and Italy. The Company also has investments in subsidiaries engaged in insurance operations in California, primarily in property and casualty insurance. In December 2013, the Company announced that it has acquired two transfer stations in Northern New Jersey from Advanced Disposal.

Blikk Holding

Acquisition in 2021
The blikk group is a growing network of radiological, nuclear medicine and nephrology practices using dialysis. As a reliable partner for patients and referring physicians, the practices of the association make a significant contribution to high-quality medical care. They all share the common claim to the highest quality and excellent education and training of medical and non-medical staff in all disciplines.

Xilis

Series A in 2021
Xilis, Inc. develops next generation organoid technologies to guide precision therapy for cancer patients and improve drug discovery. It offers The XilisµO, a platform that enables rapid diagnostics, personalized drug screening, and scalable patient-derived models for high-throughput drug discovery. Xilis, Inc. was founded in 2019 and is based in Chapel Hill, North Carolina.

Cypress Creek Renewables

Acquisition in 2021
Cypress Creek Renewables is a leading American company specializing in local solar energy solutions. The firm employs a data-driven strategy to identify and acquire underutilized land for the development of solar farms, typically ranging from 2 to 20 megawatts. Notably, Cypress owns the largest solar farm east of the Mississippi River. The company partners with landowners, utility providers, and local vendors to develop, finance, and operate both utility-scale and distributed solar projects. In addition to generating renewable energy, Cypress offers asset management, fleet ownership, and maintenance services for its own and third-party solar and storage assets. By selling the electricity produced by its solar farms back to local communities at competitive rates, Cypress Creek Renewables ensures widespread access to clean and affordable energy.

PAREXEL

Acquisition in 2021
PAREXEL International Corporation is a biopharmaceutical services company that supports the pharmaceutical, biotechnology, and medical device industries globally. Founded in 1983 and headquartered in Waltham, Massachusetts, the company operates through three main segments: Clinical Research Services (CRS), PAREXEL Consulting and Medical Communications Services (PCMS), and Perceptive Informatics. The CRS segment specializes in managing various aspects of clinical trials, including study design, patient recruitment, data management, and pharmacovigilance. The PCMS segment offers consulting services in areas such as drug development, regulatory affairs, and market access, assisting clients with product launch strategies and commercialization challenges. The Perceptive segment focuses on technology solutions, providing services like medical imaging, systems integration, and data management tools. By delivering a comprehensive range of services, PAREXEL aims to facilitate scientific discoveries and enhance the drug development process for its clients.

PRO Unlimited

Acquisition in 2021
PRO Unlimited Inc. specializes in contingent workforce management solutions for Global and Fortune 500 companies. Founded in 1991 and headquartered in Boca Raton, Florida, the company addresses the complexities of managing temporary and independent workers, including contractors, consultants, and freelancers. PRO Unlimited offers a vendor-neutral Managed Services Program that assists clients in procurement, selection, engagement, and tracking of contingent labor. Its software-as-a-service platform, known as Vendor Management System (VMS), centralizes various aspects of workforce management, enabling organizations to control quality, manage costs, and ensure compliance. Additionally, the RatePoint application provides on-demand intelligence regarding rates and hiring for professional contingent positions. By focusing on issues such as supplier management, worker classification, lifecycle tracking, and co-employment, PRO Unlimited helps clients navigate the challenges associated with a growing contingent workforce. The company has expanded its presence internationally, with locations in the United Kingdom, Japan, California, New York, and Hong Kong.

Mollie

Series C in 2021
Mollie B.V. is a payments platform that specializes in online payment processing for merchants. Founded in 2004 and headquartered in Amsterdam, the Netherlands, Mollie serves over 50,000 clients by providing an easy-to-implement solution for integrating various payment methods into websites and applications. The platform supports a wide range of local payment options, including Mastercard, VISA, PayPal, iDEAL, and Bitcoin, among others. Mollie focuses on simplifying the payment process for merchants, eliminating complexities associated with multiple payment methods through a powerful and user-friendly API. The company emphasizes technology, innovation, and reliability in its services.

Solarpack

Acquisition in 2021
Solarpack focuses in the development and operation of large-scale photovoltaic solar projects. The company also has a consulting department that advises international customers in all areas of solar photovoltaic energy. The company global divisions which are development and construction, power generation, and services, represent an attractive and well-balanced combination of long term stable revenues with less recurrent yet highly profitable activities. It operates and maintains 13 plants, with a total capacity of 160 MW, and provides asset management services for a total of 302 MW of projects. The company also has a diversified geographical presence and employs over 140 people in 10 countries. Founded on 2005, Solarpack is a solid and solvent company, capable of executing quality and valuable projects for the society and the environment. It contributes directly to the social development of the communities and markets in which it operates, through the creation of economic value, and also through the generation of quality employment and through the social projects it promotes. It is headquartered in Getxo, Vizcaya in Spain.

Parcel2Go

Acquisition in 2021
Parcel2go.Com Ltd provides parcel delivery services in the United Kingdom. Its services includes myHermes ParcelShop; allows to drop off parcel at one of many outlets hence saving having to wait in for the driver to collect, DPD Drop-off; allows to drop parcel off at any of the DPD locations around the UK, UPS Standard; recognizes parcel couriers with brown vans and uniforms, Parcelforce Worldwide 48; allows to drop parcel in to a local Post Office, TNT UK Express, and Letters and Small Parcels by Whistl. The company was founded in 1991 and is based in Bolton, United Kingdom.

Anticimex AB

Venture Round in 2021
Anticimex is a global specialist in preventive pest control with operations in 17 counties across Europe, Asia-Pacific and the US with headquarters in Stockholm, Sweden. With its approximately 4,500 employees, Anticimex serves more than 3 million customers across the globe and offers a broad range of preventive pest control solutions, including the digital solution Anticimex SMART and pest insurance.

ManyPets

Series D in 2021
Bought By Many is the multi-award-winning pet insurance provider that is disrupting insurance distribution. They do this by analysing anonymised internet search data and customer research to identify unmet consumer needs for insurance. Key company milestones are as follows: o 2012: Launched boughtbymany.com. Completed seed funding round. o 2013: Named Insurance Website of the Year. o 2014: Identified by Boston Consulting Group & Morgan Stanley as the global exemplar of innovation in insurance distribution. Awarded Best Use of Mobile Technology at the Digital Insurance Awards. o 2015: Surpassed 100,000 members. Launched SaaS platform in China in partnership with Ping An Insurance. Completed second funding round. Became directly regulated by the FCA. Acquired Brooks Braithwaite (Sussex) Ltd - the UK’s leading provider of insurance for exotic pets and pet businesses. Named Fintech Innovation of the Year & Insurance Start Up of the Year. o 2016: Innovation in Insurance Award at the Fintech Innovation Awards. Named in the FinTech 50. Signed long-term insurance agreement with Munich Re. Completed Series A funding round. o 2017: Launched Bought By Many-branded cat and dog insurance product range. o 2019: Named most trusted pet insurance provider at the 2019 Moneywise Customer Service Awards. Launched Bought By Many cat and dog insurance in Sweden. o 2020: Covers more than 200,000 pets in the UK. They have an exceptional team of 150, based across sites in Farringdon, Central London; Haywards Heath, Sussex; Birmingham; and Sweden. They're always interested to hear from people who'd like to learn about career opportunities at Bought By Many, and they're currently recruiting for web development, business analysis, & project management roles.

DESOTEC

Private Equity Round in 2021
Founded in 1990, Desotec has pioneered the market for the purification of liquids and gases through mobile activated carbon filters. During its more than 25 years in business, the company has established itself as a European market leader in this field. Desotec provides a filtration technology that enables its customers to comply with increased environmental regulations and sustainability requirements and to serve mission-critical filtration needs offering a flexible rental solution.

Binx Health

Series E in 2021
Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, specializing in the development of diagnostic instruments and disposable cartridge systems for decentralized laboratory and point-of-care environments. The company's flagship products include the io System, which detects infectious diseases such as chlamydia and MRSA, and Callisto, designed to accommodate various testing throughput requirements. Binx Health focuses on providing solutions for sexually transmitted infections and hospital-acquired infections. The company aims to enhance healthcare accessibility by delivering on-demand testing directly to consumers, utilizing its proprietary, desktop, PCR-based platforms and mobile offerings. Established in 2005, Binx Health has formed a strategic partnership with Sherlock Biosciences to further advance its innovative healthcare solutions.

Vinted

Series F in 2021
Vinted operates an online marketplace intended to make second-hand the first choice. Its platform offers a peer-to-peer marketplace for girls and women to buy, sell, and swap clothes with an online chatting feature, enabling users to shop with ease at low cost.

First Transit

Acquisition in 2021
First Transit is a public transit management operator that transports over 300 million passengers annually across around 300 locations in North America. First Transit provides essential mobility services to communities, college campuses, businesses, and elderly care facilities that are economical, safe, and environmentally friendly.

First Student

Acquisition in 2021
First Student, Inc., is a school bus operator, provides student transportation services for schools and districts.

Onward

Venture Round in 2021
Onward is developing an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools to rehabilitate patients suffering from neurological disorders such as spinal cord injury (SCI).

Cerba HealthCare S.A.S.

Acquisition in 2021
Cerba HealthCare S.A.S., is a clinical pathology laboratory, provides routine and specialized clinical laboratory testing services.

Epidemic Sound

Private Equity Round in 2021
Epidemic Sound is a Swedish based music company soundtracking the new generation of video creators. By working directly with composers and owning the music 100%, the company has built a model perfect for online video. Customers subscribe for unlimited use or license individual tracks. All music usage includes clearance on all platforms, worldwide, for all time. The company's catalogue has over 30 000 tracks, spaning over 180 genres, in prime time broadcast quality. Epidemic Sound was founded on 2009 and is headquartered in Stockholms, Sweden.

Supplant

Series A in 2021
Cambridge Glycoscience is a biotechnology company based in London, United Kingdom, founded in 2017. The company specializes in developing sugar-free ingredients for the food industry, focusing on creating natural food components derived from agricultural resources. Their innovative products enable food manufacturers to reduce sugar content, enhance fiber levels, and improve gut health-promoting qualities in food items. By leveraging biotechnology, Cambridge Glycoscience aims to support healthier eating options and contribute to the evolving landscape of food production.

CYE

Series A in 2021
CYE provides innovative and cost effective cybersecurity solutions, combining for the first time advanced artificial intelligence with exceptional natural intelligence, along with services that are delivered by world leading security experts.

IVC Evidensia

Private Equity Round in 2021
Provider of veterinary care services with clinics spread across Europe. The company has an expansive network of clinics, hospitals, and out-of-hour centers, thereby serving pet owners and guiding them on balanced nutrition for every animal, regardless of breed, age, and gender.

Exeter Property Group

Acquisition in 2021
Exeter Property Group, established in 2006, is a real estate investment manager that specializes in U.S. investments in value-added and core properties. The company is led by a team with over 25 years of experience across various real estate market cycles. Exeter's investment strategy centers on assembling diversified property portfolios that cater to tenant needs for value and functionality. This approach aims to generate superior returns through high levels of cash flow, value-add growth, and capital appreciation potential. With regional offices throughout the U.S., Exeter employs a tenant-focused strategy that enables direct engagement in property selection and management.

Wolt

Series E in 2021
Wolt is a Helsinki-based company that specializes in food delivery services, enabling users to conveniently discover and order meals for home or office delivery. The platform offers a mobile interface that facilitates access to a variety of dining options, including takeaway services. Since its inception, Wolt has attracted significant investment, raising $280 million from notable investors such as ICONIQ Capital, Highland Europe, 83North, EQT Ventures, and Goldman Sachs.

XyloCor Therapeutics

Venture Round in 2021
XyloCor Therapeutics is a biopharmaceutical company focused on developing gene therapies for cardiovascular diseases, particularly for patients with advanced coronary artery disease. Founded in 2013 and based in Newtown Square, Pennsylvania, the company is working on innovative treatments such as XC001, an investigational gene therapy aimed at patients suffering from refractory angina who have limited treatment options. Another product in development, XC002, targets the regeneration of cardiac tissue in individuals with impaired heart function due to previous heart attacks and heart failure. XyloCor's therapies aim to stimulate the formation of new coronary blood vessels, providing essential blood supply to areas of the heart that are currently underserved, ultimately offering a more effective and less painful solution for those affected by these serious conditions.

Neurent Medical

Series B in 2021
Neurent Medical Limited develops medical device for treating rhinitis. The company offers a single-use device for ENT surgeons to treat both allergic and non-allergic rhinitis. The company was founded in 2015 and is headquartered in Galway, Ireland.

think project! GmbH

Seed Round in 2020
think project! is a cloud solution for cross-enterprise collaboration, tailored to the needs of construction and engineering projects. The name think project! stands for both a flexible software solution, which can be adapted to individual needs with little effort, and a team of specialists who implement cross-enterprise collaboration according to their customers’ individual requirements. think project! companies.

Storable

Acquisition in 2020
Storable is a provider of self-storage management software designed to enhance operational efficiency and profitability for storage operators. Its Storable Platform offers a comprehensive suite of technology solutions, including management software, marketing websites, tenant insurance, payment processing, and access to the industry's largest storage marketplace. This integrated approach allows customers to compare various storage options across the nation, enabling them to select the most suitable and cost-effective solutions for their needs, whether they require traditional self-storage or full-service storage options.

Molslinjen

Acquisition in 2020
Molslinjen is a privately held company that operates ferry services between the Jutland and the island of Zealand.

Beijer Ref

Secondary Market in 2020
Beijer Ref is a technology-oriented trading group that, through value-added products, offers its customers competitive solutions in refrigeration and air conditioning.

think project! GmbH

Acquisition in 2020
think project! is a cloud solution for cross-enterprise collaboration, tailored to the needs of construction and engineering projects. The name think project! stands for both a flexible software solution, which can be adapted to individual needs with little effort, and a team of specialists who implement cross-enterprise collaboration according to their customers’ individual requirements. think project! companies.

Livekindly

Venture Round in 2020
Livekindly, Inc., based in Vancouver, Canada, is a collective focused on promoting sustainable living through various platforms. The company operates a media outlet that publishes news and stories about health, ethics, and the environment, while also providing resources such as vegan recipes and information on plant-based restaurants and vacations. Livekindly encompasses several brands, including The Fry Family Food Co. and LikeMeat, and is dedicated to transforming the global food system by producing plant-based alternatives that do not rely on animal products. The company manages the entire value chain for its products, from seed growers to distributors, and actively partners with poultry production companies to develop plant-based options. Additionally, Livekindly offers a membership program, Kindmind, which provides plant-based meal plans and expert consultations, fostering a community committed to sustainable and compassionate living.

Cardiac Dimensions

Series C in 2020
Cardiac Dimensions, Inc., a medical device company, engages in the development of minimally invasive treatment modalities to address heart failure and related cardiovascular conditions. The company develops Carillon Mitral Contour System, a permanent implant for the treatment of functional mitral regurgitation. The company was incorporated in 2000 and is based in Kirkland, Washington with additional operations in Sydney, Australia and Offenbach, Germany.

Oterra

Acquisition in 2020
Chr Hansen - Natural Colors is a developer and manufacturer of natural coloring ingredients for food and beverages.

Casa.it

Acquisition in 2020
Casa.it is a provider of online real estate advertising services. It offers information on real estate agencies, on sale, and for rent properties comprising of flats, villas, independent houses, penthouses, loft, and others, and private space on the internet. It was founded in 1996 and is headquartered in Milan, Italy.

idealista

Acquisition in 2020
idealista.com is a real estate website in Spanish. idealista.com is a meeting point for buyers and sellers and its database consists currently of more than 280,000 unique listings; also provides the buyer and the seller with useful information to help and guide them in their buying-selling. Since 2000, idealista.com has been specializing in helping millions of people overcome the anxiety and frustration of finding a home.

Colisée

Acquisition in 2020
Colisée is a key player in the global health care and old-age dependency sector, and has developed a real expertise in elderly people care and well-being. Its network includes 90 facilities in France, Italy and Spain and close to 70 home-based services agencies in France. In those two business segments, Colisée employs more than 6,700 people.

Depict

Seed Round in 2020
Depict.ai develops a product recommendation engine aimed at enhancing the quality of product suggestions for e-commerce stores. By providing advanced recommendation capabilities similar to those found on major platforms, the company enables smaller businesses to compete effectively against larger competitors. The software is designed to increase overall revenue for e-commerce sites without requiring extensive sales data, thereby democratizing access to high-quality recommendations. Through its innovative approach, Depict.ai seeks to empower smaller players in the e-commerce market, allowing them to improve customer engagement and drive sales.

EdgeConneX

Acquisition in 2020
Edge Services provide Space, Power & Connectivity to deliver digital content like never before. With EdgeConneX, data delivery is optimized by placing Edge Data Centers®, Edge Small Cells and Edge PoPs® at the most critical locations—as close as possible to the end user’s point of access. By using our services, digital content is delivered with higher performance and lower latency to any device, anywhere.

Vico Therapeutics

Series A in 2020
Vico Therapeutics B.V., founded in 2019 and based in Leiden, the Netherlands, specializes in developing RNA modulating therapies aimed at treating rare neurological disorders. The company focuses on conditions such as spinocerebellar ataxias, Huntington's disease, and Rett syndrome. By leveraging innovative approaches to RNA therapy, Vico Therapeutics aims to address the unmet medical needs of patients with central nervous system disorders, particularly those that are hereditary or neurodevelopmental in nature. The company is committed to discovering, developing, and delivering effective treatments to improve the quality of life for individuals affected by these conditions.

DNA Script

Series B in 2020
DNA Script SAS, founded in 2014 and based in Paris, France, specializes in synthetic biology tools. The company focuses on developing innovative DNA synthesis solutions, including oligonucleotides, genes, pathways, and genomes. Its flagship product, the SYNTAX benchtop DNA printer, utilizes groundbreaking enzymatic technology, allowing laboratories to produce their own synthetic oligonucleotides. This capability enhances workflow control and accelerates access to results, thereby facilitating advancements in life sciences and human health.

VarmX

Series B in 2020
VarmX B.V., a biotechnology company, develops therapies in the field of hemostasis and thrombosis. It develops PseudoXa, a therapeutic protein that is used to stop bleeding of patients who use blood thinners. The company was founded in 2016 and is based in Leiden, the Netherlands.

ViCentra

Venture Round in 2020
ViCentra B.V., based in Utrecht, the Netherlands, specializes in the development of medical devices, particularly for diabetes management. The company focuses on creating user-friendly and aesthetically pleasing products that aim to enhance the overall experience for individuals managing their health. ViCentra emphasizes the importance of excellent customer experiences and approaches product design with the belief that simplicity and effectiveness lead to better health outcomes. In addition to its operations in the Netherlands, ViCentra also has a presence in the UK, where it continues to innovate in the field of medical devices through dedicated research and development efforts.

Cybin

Series B in 2020
Cybin is a biopharmaceutical company dedicated to developing safe and effective therapeutics using psychedelic and medicinal mushrooms. The company focuses on creating psilocybin-based products in regions where such substances are permitted, while also conducting clinical studies across North America and other areas through collaborations with academic and institutional partners. Cybin's efforts encompass the advancement of psychedelic-based therapies, innovative delivery mechanisms, and the development of novel compounds aimed at addressing a range of mental health issues, including various psychiatric and neurological conditions.

LUMA Vision

Series A in 2020
OneProjects Design and Innovation Ltd. develops healthcare technologies for the treatment of cardiac arrhythmias. It offers VERAFEYE, a connected platform technology to revolutionize the treatment of AFib and cardiac arrhythmias. The company was incorporated in 2017 and is based in Dublin, Ireland.

Freepik

Acquisition in 2020
Freepik is a search engine that helps graphic and web designers to locate high quality photos, vectors, illustrations and PSD files for their creative projects. Freepik tracks and locates free graphic content on the Internet and it displays the results in an orderly layout for easy access. Freepik makes it easier for people to find the files they need without manually searching dozens of websites.

Arvelle Therapeutics

Series A in 2020
Arvelle Therapeutics GmbH, a biopharmaceutical company, focuses on solutions for patients suffering from CNS disorders. It is involved in the development and commercialization of cenobamate, an investigational antiepileptic drug in the European market. The company was founded in 2019 and is headquartered in Zug, Switzerland.

Kiadis Pharma

Post in 2020
Kiadis Pharma N.V. is a biopharmaceutical company based in Amsterdam, specializing in cell-based immunotherapy products for blood cancer treatment. The company is developing K-NK002, currently in Phase II clinical trials, as an adjunctive immunotherapeutic for blood cancer patients undergoing haploidentical hematopoietic stem cell transplantation with the post-transplant cyclophosphamide protocol. K-NK003 is another product in Phase I/II trials, targeting patients with acute myeloid leukemia relapse or refractory cases. Additionally, Kiadis Pharma is working on K-NK00X, a preclinical NK-cell therapy candidate aimed at treating various solid tumors. The company has established collaborations for the development of a combination therapy involving monoclonal antibodies and natural killer cells to address COVID-19. Kiadis Pharma focuses on addressing the complications and limitations associated with hematopoietic stem cell transplants, offering novel treatment options for terminally ill cancer patients with significant unmet medical needs.

FoRx Therapeutics

Seed Round in 2020
FoRx Therapeutics AG is a biotechnology company based in Basel, Switzerland, founded in 2019. The company specializes in developing first-in-class therapeutic compounds for cancer treatment by targeting key molecular mechanisms related to DNA replication stress. This innovative approach aims to create targeted anticancer drugs that address critical aspects of cancer biology. As a privately-held entity, FoRx Therapeutics is committed to advancing its research and development efforts in the oncology space.

Schülke & Mayr GmbH

Acquisition in 2020
Schülke & Mayr GmbH is a company that develops, manufactures, and supplies a diverse range of hygiene and care products, including disinfectants, antiseptics, preservatives, biocides, and medical skin care items. Founded in 1889 and headquartered in Norderstedt, Germany, the company serves various sectors, offering specialized hygiene management solutions aimed at preventing hospital-acquired infections, as well as professional hygiene products for medical practices and outpatient facilities. Its industrial hygiene solutions cater to industries such as food processing and pharmaceuticals, while its preservatives are used in cosmetics, household products, coatings, and metalworking. Schülke & Mayr GmbH operates globally with subsidiaries in multiple countries, including Australia, France, India, and the United States, and functions as a subsidiary of L'Air Liquide S.A.

Dukes Education Group

Debt Financing in 2020
Dukes Education is a university preparation provider that supports students of all ages to develop academic excellence.

Deutsche Glasfaser

Acquisition in 2020
Deutsche Glasfaser Holding GmbH, established in 2012 and headquartered in Borken, Germany, specializes in operating fiber optic networks and delivering broadband telecommunication services. The company focuses on expanding high-speed internet access, particularly in underserved areas of Germany. As of May 2020, Deutsche Glasfaser operates as a subsidiary of inexio Beteiligungs GmbH & Co. KGaA, reflecting its strategic alignment within a larger telecommunications framework.

Rimes Technologies

Private Equity Round in 2020
RIMES Technologies provide specialist managed data services to investment managers and asset owners worldwide. They deliver cloud-based services that help our clients reduce the cost of managing financial data while lowering operational risk. With 20 years’ experience, no one knows as much about financial benchmarks as we do. They are the world’s first managed data service provider for investment managers and asset owners, and a trusted partner to our customers.

O2 Power

Private Equity Round in 2020
O2 Power Private Limited develop and execute utility scale renewable energy project. The company was incorporated in 2019 and is based in Gurugram, India.

Health Management International

Private Equity Round in 2020
Health Management International Ltd is a growing regional private healthcare provider with presence in Singapore, Malaysia and Indonesia. The Group owns two tertiary hospitals in Malaysia, a healthcare training centre in Singapore and a network of representative offices in Indonesia, Malaysia and Singapore.

SHL Group

Private Equity Round in 2020
SHL Group, based in Zug, Switzerland, specializes in the design, development, and manufacturing of advanced drug delivery systems, including auto injectors, pen injectors, and inhaler systems. Founded in 1989, the company provides comprehensive services, such as final assembly, labeling, and packaging, for pharmaceutical and biotech firms globally. SHL Group prioritizes compliance with strict regulations and upholds high-quality standards in its operations. The company emphasizes the importance of talent development and collaboration among its employees to enhance productivity and customer satisfaction. By focusing on these core principles, SHL Group aims to deliver superior business outcomes while maintaining professionalism in all aspects of its work.

Recover Nordic Norge

Acquisition in 2019
Recover Nordic Norge is the largest emergency response and damage control business in the Nordic region.

Mabtech

Debt Financing in 2019
Mabtech AB is a biotechnology company based in Stockholm, Sweden, founded in 1986. The company specializes in the development, manufacturing, and marketing of monoclonal antibodies and various assay kits, including those for enzyme-linked immunoassays such as ELISA, ELISpot, and FluoroSpot. Mabtech's product range includes monoclonal antibodies for a variety of applications, as well as specialized kits for detecting cytokines and other immunological molecules in biological samples from multiple species, including humans and various animals. The company aims to support the global scientific community by providing efficient tools that streamline the biomedical research process. Mabtech operates internationally, with locations in the United States, Australia, Germany, and France, and offers its products online. It is a subsidiary of Mabtech Group AB.

ImCheck Therapeutics

Series B in 2019
ImCheck Therapeutics SAS is a biotechnology company incorporated in 2015 and based in Marseille, France. The company specializes in designing and developing immunotherapeutics that target the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. With a primary focus on immuno-oncology, ImCheck Therapeutics develops immunomodulatory antibodies aimed at treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company is dedicated to addressing severe unmet medical needs through its innovative approach to cancer treatment and the development of next-generation immunotherapeutics.

Galderma

Acquisition in 2019
Galderma S.A. is a global company specializing in the manufacture and distribution of medical, consumer skin health, and dermatology products. Founded in 1981 and headquartered in Lausanne, Switzerland, Galderma offers a wide range of solutions including prescription medicines, medical aesthetics, and skincare products. Its extensive product portfolio addresses various dermatological conditions such as acne, rosacea, psoriasis, and skin cancer, with well-known brands like Epiduo®, Differin®, and Restylane®. The company operates through a network of 33 wholly-owned affiliates and distributors in approximately 80 countries, employing around 6,600 people. Galderma emphasizes innovation in meeting the dermatological needs of individuals and healthcare professionals, with research and development, and manufacturing sites located across multiple regions including Europe, Asia-Pacific, and the Americas.

inexio

Acquisition in 2019
Inexio is a technology company that specializes in telecommunications and information technology services, focusing on fiber-based internet access for corporations and medium-sized businesses. The company provides broadband connections through a fiber-optic network and is actively involved in the development and expansion of modern telecommunications infrastructure. Inexio also offers data center services, supporting businesses in their IT needs and enhancing connectivity and operational efficiency.

CTEK

Debt Financing in 2019
CTEK Sweden AB is a prominent manufacturer of battery chargers, specializing in 12V chargers for a range of vehicles in the premium segment. The company stands as Sweden's second largest supplier of chargers and accessories for electric vehicle charging, highlighting its significant role in the evolving automotive market. With a focus on delivering high-quality products, CTEK is recognized for its innovative solutions that cater to the needs of both conventional and electric vehicle users.

Pharvaris

Series B in 2019
Pharvaris B.V. is a clinical-stage company based in Leiden, the Netherlands, focused on the discovery and development of oral bradykinin B2 receptor antagonists for the treatment of hereditary angioedema (HAE) and other conditions linked to B2 receptor activity. Established in 2015, the company aims to provide new therapeutic options that eliminate the need for injections. Its lead drug candidate, PHA121, is a novel small-molecule antagonist currently undergoing Phase 1 clinical trials. Pharvaris benefits from the expertise of its co-founders, including an inventor of icatibant, which is a previously developed treatment for HAE. The company is dedicated to advancing alternatives to existing therapies, enhancing the quality of life for patients with HAE.

Nkarta Therapeutics

Series B in 2019
Nkarta, Inc., a biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company’s approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its co-lead product candidates are NKX101, a pre-clinical product that enhances the power of innate NK biology to detect and kill cancerous cells; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded in 2015 and is headquartered in South San Francisco, California.

Ellab

Acquisition in 2019
Ellab is a global supplier of thermal validation and monitoring solutions, specializing in wireless data loggers and thermocouple systems. The company provides a range of high-precision, modular products designed to measure, record, monitor, and validate critical parameters in thermal processing. Its offerings include data loggers, thermocouple-based instruments, and validation equipment, which are utilized in various applications such as sterilization, freeze-drying, environmental chambers, heat tunnels, and pasteurization. Operating in over 65 countries, Ellab focuses on reducing time-to-market and minimizing the risk of product loss for its clients.

Nexon Asia Pacific

Acquisition in 2019
Nexon Asia Pacific Pty. Ltd. is an end-to-end managed IT provider based in Sydney, Australia, with additional offices in Brisbane and Summer Hill. Established in 2000, the company offers a comprehensive range of information technology consulting and solutions, focusing on voice and communications, network management, infrastructure, business continuity, and security. Its voice and communications solutions include PBX, contact center technology, and video conferencing, while network solutions encompass managed private networks, business Internet, and WAN optimization. The company also provides infrastructure services such as infrastructure-as-a-service and storage-as-a-service, alongside business continuity solutions like backup and disaster recovery services. Security offerings include managed firewalls and intrusion prevention systems. Nexon Asia Pacific serves various sectors, including aged care, healthcare, government, legal services, and retail, delivering its products and services through a network of resellers and partners.

Amolyt Pharma

Series A in 2019
Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company's leading programs include AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining sustained calcium levels in the blood, and AZP-3404, which features a novel mechanism of action that may help restore fat and glucose metabolism. Through its innovative approach, Amolyt Pharma seeks to provide effective treatments for patients suffering from critical and rare metabolic conditions.

Aldevron

Acquisition in 2019
Aldevron provides contract manufacturing and scientific services. It specializes in plasmid DNA, protein production, and antibody generation. It combines best-in-class products and service with the ideal operating environment to lay the groundwork for vital new discoveries worldwide. Its services include Plasmid DNA Production, Protein Production, Antibody Discovery, mRNA Production, and other related services. It was founded in 1998 and is headquartered in Fargo, North Dakota, United States.

Waystar

Acquisition in 2019
Waystar is a provider of cloud-based technology that streamlines the healthcare revenue cycle for various organizations, including providers, hospitals, and health systems. The platform enhances data integrity and improves the accuracy of claims and billing processes, facilitating better transparency and reducing labor costs. By simplifying the complexities involved in healthcare payments, Waystar enables clients to focus on their core missions and patient care. The company has received multiple accolades, including Best in KLAS® rankings for claims clearinghouse and top ratings for medical claims processing and patient payment solutions. Serving over 400,000 healthcare organizations, Waystar partners with leading electronic health record and practice management solution providers to deliver comprehensive and efficient services across the United States and its territories.

AM Pharma

Series F in 2019
AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derived peptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.